NOVOSEVEN RT eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe

Опис товару

About NOVOSEVEN RT eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe

NOVOSEVEN RT eptacog alfa (activated) (bhk) 2mg powder for injection vial with pre-filled diluent syringe is a sterile, lyophilized powder intended for intravenous administration. This medicinal product is designed for clinical use in specific patient populations requiring coagulation factor replacement therapy. Each kit includes a single-use vial containing the active substance and a pre-filled syringe containing the necessary diluent for reconstitution. The product must be prepared according to the provided instructions to ensure proper concentration and stability before administration. It is essential that this medication is handled by trained healthcare professionals or patients who have received appropriate training in self-administration techniques. Proper storage conditions must be maintained to preserve the integrity of the protein components within the vial.

Key Benefits & Uses

• Provides a concentrated form of activated coagulation factor VII for therapeutic use.
• Includes a pre-filled syringe to facilitate accurate and efficient reconstitution of the powder.
• Designed for clinical management of bleeding episodes in patients with specific clotting factor deficiencies.

Active Ingredient & Action

The active ingredient in this product is eptacog alfa (activated), which is a recombinant human coagulation factor VIIa. It also contains histidine as a buffering agent. This protein works by promoting the formation of a hemostatic plug at the site of injury, thereby assisting in the blood coagulation process.

Important Notes

This product is a prescription medication and should only be used under the direct supervision of a qualified physician. Always check the expiration date on the packaging before use. Do not use the product if the seal is broken or if the solution appears cloudy after reconstitution. Consult the full prescribing information for detailed dosage guidelines and administration protocols.